Evidence map›Paper›PMID 35178254›Full record

ArticleInternational journal of nephrology2022

Kidney-Related Outcome in Cardiorenal Syndrome Type 3.

Kim Drubel, Benedikt Marahrens, Oliver Ritter, Daniel Patschan

Abstract read
In one paragraph

Article in International journal of nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Metabolomics in Acute Kidney Injury: The Experimental Perspective.Journal of clinical medicine research · 2023
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kim DrubelKlinik für Kardiologie und Nephrologie, University Hospital Brandenburg, Medical School of Brandenburg, Brandenburg, Hochstraße 29, 14770 Brandenburg, Germany.ORCID https://orcid.org/0000-0002-9533-7663
Benedikt MarahrensKlinik für Kardiologie und Nephrologie, University Hospital Brandenburg, Medical School of Brandenburg, Brandenburg, Hochstraße 29, 14770 Brandenburg, Germany.ORCID https://orcid.org/0000-0002-6234-5229
Oliver RitterKlinik für Kardiologie und Nephrologie, University Hospital Brandenburg, Medical School of Brandenburg, Brandenburg, Hochstraße 29, 14770 Brandenburg, Germany.ORCID https://orcid.org/0000-0003-4172-9378
Daniel PatschanKlinik für Kardiologie und Nephrologie, University Hospital Brandenburg, Medical School of Brandenburg, Brandenburg, Hochstraße 29, 14770 Brandenburg, Germany.ORCID https://orcid.org/0000-0002-6914-5254

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

methodsA single-center, retrospective and observational trial. All subjects with positive AKI alert, treated at the University Hospital Brandenburg between January and December 2019, were evaluated. Definition of CRS type 3 was according to predefined criteria. The three endpoint categories were in-hospital death, dialysis, and recovery of kidney function.

results. A total number of 1,334 AKI alerts were screened. Finally, 95 subjects received the diagnosis CRS type 3. The survival rates were 47.1% (females) and 43.6% (males). 46.8% of affected females and 33.3% of the males required dialysis therapy. Complete recovery at the time of discharge occurred in 35.8%, and no recovery at all was found in 54.7%.

conclusions. All three predefined study endpoints, the mortality, the prevalence of dialysis, and the percentage of subjects without recovery of kidney function, were notably high. Therefore, AKI patients with imminent or established cardiac complications require the highest attention of nephrologists in charge.

Identifiers

PMID35178254
PMCPMC8844349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.